Latest Pharma Insights
Finance Watch: Sage Executives Return With A New Neurology Start-Up
Private Company Edition: Tortugas Neuroscience emerged with $106m and in-licensed clinical drug candidates, with former Sage CEO Jeff Jonas and CSO Al Robichaud at the helm. Also, Ray Therapeutics raised a $125m series A round and Flagship launched Serif with $50m.
Scrip - April 27, 2026
Private Company Edition: Tortugas Neuroscience emerged with $106m and in-licensed clinical drug candidates, with former Sage CEO Jeff Jonas and CSO Al Robichaud at the helm. Also, Ray Therapeutics raised a $125m series A round and Flagship launched Serif with $50m.
Scrip - April 27, 2026
Premium Supplements Grow But Nutrition Sales Down For Nestlé
Infant formula recall hits sales at Nestlé's Nutrition business, which now houses the firm's dietary supplement lines following an organizational shake-up.
HBW Insight - April 27, 2026
Infant formula recall hits sales at Nestlé's Nutrition business, which now houses the firm's dietary supplement lines following an organizational shake-up.
HBW Insight - April 27, 2026
Outgoing Santhera CEO Reflects On Firm’s Remarkable Recovery
Having joined in 2019, faced with a failed lead asset and financial dire straits, Dario Eklund is leaving the Swiss firm in rude health as its Duchenne drug, Agamree, continues to expand.
Scrip - April 27, 2026
Having joined in 2019, faced with a failed lead asset and financial dire straits, Dario Eklund is leaving the Swiss firm in rude health as its Duchenne drug, Agamree, continues to expand.
Scrip - April 27, 2026
Debt To Scale: Shanghvi’s Bold Organon Deal Signals A New Sun Is Rising
Sun’s acquisition of Organon positions it for striking global scale including in markets like China, diversified growth across women’s health, biosimilars and innovative drugs, setting it up for long-term value creation.
Scrip - April 27, 2026
Sun’s acquisition of Organon positions it for striking global scale including in markets like China, diversified growth across women’s health, biosimilars and innovative drugs, setting it up for long-term value creation.
Scrip - April 27, 2026
Hikma Abandons 503B Compounding And Strikes Fresh Inhalers Deal
Recently-reinstalled Hikma CEO Said Darwazah is wasting no time in taking action to turn the business around and restore focus, bringing to an end the company’s 503B compounding venture in the US at the same time as striking a fresh device technology to support its planned generic Ellipta inhalers.
Generics Bulletin - April 27, 2026
Recently-reinstalled Hikma CEO Said Darwazah is wasting no time in taking action to turn the business around and restore focus, bringing to an end the company’s 503B compounding venture in the US at the same time as striking a fresh device technology to support its planned generic Ellipta inhalers.
Generics Bulletin - April 27, 2026
Eli Lilly Goes From Backer To Buyer With Ajax Deal
Ajax is Lilly's sixth acquisition of 2026 and its second blood-cancer deal in a week.
Scrip - April 27, 2026
Ajax is Lilly's sixth acquisition of 2026 and its second blood-cancer deal in a week.
Scrip - April 27, 2026
Editing Heart Disease Out Of Our DNA
Gene editing medicines for cardiovascular risk are fast becoming a reality, with early data that dwarfs the impact of statins.
In Vivo - April 27, 2026
Gene editing medicines for cardiovascular risk are fast becoming a reality, with early data that dwarfs the impact of statins.
In Vivo - April 27, 2026
Formycon Sets Out Growth Strategy After Missing FY2025 Financial Guidance
German biosimilars developer Formycon presented a four-pillar strategy to drive geographic expansion, portfolio growth, operational excellence, and cost efficiency, as it targets positive €60m-€70m in revenue for 2026.
Generics Bulletin - April 27, 2026
German biosimilars developer Formycon presented a four-pillar strategy to drive geographic expansion, portfolio growth, operational excellence, and cost efficiency, as it targets positive €60m-€70m in revenue for 2026.
Generics Bulletin - April 27, 2026
Sun Speeds Into Biosimilars With $11.75bn Organon Platform
Sun Pharma will acquire Organon in an $11.75bn deal, gaining an immediate global biosimilars platform, major China and Europe presence, while entering the world’s top 25 drugmakers after nearly doubling revenues.
Generics Bulletin - April 27, 2026
Sun Pharma will acquire Organon in an $11.75bn deal, gaining an immediate global biosimilars platform, major China and Europe presence, while entering the world’s top 25 drugmakers after nearly doubling revenues.
Generics Bulletin - April 27, 2026
Hard-Hit UK Biotech Lifted By M&A And Financing In Q1
Many UK biotechs were starved of new funds in 2025, but the first quarter of this year saw a rise in overall dealmaking, plus two company buyouts by big pharma.
Scrip - April 27, 2026
Many UK biotechs were starved of new funds in 2025, but the first quarter of this year saw a rise in overall dealmaking, plus two company buyouts by big pharma.
Scrip - April 27, 2026
Leaders Are Paying For The Wrong Skills, Report Finds
A recent Wharton/Accenture report shows biopharma workers are overselling the wrong skills, employers are rewarding the wrong ones and AI is accelerating the gap.
In Vivo - April 27, 2026
A recent Wharton/Accenture report shows biopharma workers are overselling the wrong skills, employers are rewarding the wrong ones and AI is accelerating the gap.
In Vivo - April 27, 2026
QL Biopharm Unveils Oral Once-Weekly GLP-1 Peptide
Beijing-based QL Biopharm plans to progress the oral GLP-1 peptide ZT006 into a Phase II study to evaluate its once-weekly dosing potential in weight management in the fourth quarter.
Scrip - April 27, 2026
Beijing-based QL Biopharm plans to progress the oral GLP-1 peptide ZT006 into a Phase II study to evaluate its once-weekly dosing potential in weight management in the fourth quarter.
Scrip - April 27, 2026
Sun Makes Bold Bet With $11.75bn Organon Deal
Sun snaps up Organon in a deal that is set to transform India’s top-ranked drug maker’s standing globally, giving it global scale and a commanding position in areas like women’s health, established brands and biosimilars.
Scrip - April 27, 2026
Sun snaps up Organon in a deal that is set to transform India’s top-ranked drug maker’s standing globally, giving it global scale and a commanding position in areas like women’s health, established brands and biosimilars.
Scrip - April 27, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Iran blockade’s impact on global pharma; Bayer loyal to Europe but wants more; Kailera’s big IPO; 2025’s top drugs; Anthropic taps Novartis’s CEO.
Scrip - April 27, 2026
In this week's episode: Iran blockade’s impact on global pharma; Bayer loyal to Europe but wants more; Kailera’s big IPO; 2025’s top drugs; Anthropic taps Novartis’s CEO.
Scrip - April 27, 2026
Finance Watch: Sage Executives Return With A New Neurology Start-Up
Private Company Edition: Tortugas Neuroscience emerged with $106m and in-licensed clinical drug candidates, with former Sage CEO Jeff Jonas and CSO Al Robichaud at the helm. Also, Ray Therapeutics raised a $125m series A round and Flagship launched Serif with $50m.
Scrip - April 27, 2026
Private Company Edition: Tortugas Neuroscience emerged with $106m and in-licensed clinical drug candidates, with former Sage CEO Jeff Jonas and CSO Al Robichaud at the helm. Also, Ray Therapeutics raised a $125m series A round and Flagship launched Serif with $50m.
Scrip - April 27, 2026
Outgoing Santhera CEO Reflects On Firm’s Remarkable Recovery
Having joined in 2019, faced with a failed lead asset and financial dire straits, Dario Eklund is leaving the Swiss firm in rude health as its Duchenne drug, Agamree, continues to expand.
Scrip - April 27, 2026
Having joined in 2019, faced with a failed lead asset and financial dire straits, Dario Eklund is leaving the Swiss firm in rude health as its Duchenne drug, Agamree, continues to expand.
Scrip - April 27, 2026
Debt To Scale: Shanghvi’s Bold Organon Deal Signals A New Sun Is Rising
Sun’s acquisition of Organon positions it for striking global scale including in markets like China, diversified growth across women’s health, biosimilars and innovative drugs, setting it up for long-term value creation.
Scrip - April 27, 2026
Sun’s acquisition of Organon positions it for striking global scale including in markets like China, diversified growth across women’s health, biosimilars and innovative drugs, setting it up for long-term value creation.
Scrip - April 27, 2026
Eli Lilly Goes From Backer To Buyer With Ajax Deal
Ajax is Lilly's sixth acquisition of 2026 and its second blood-cancer deal in a week.
Scrip - April 27, 2026
Ajax is Lilly's sixth acquisition of 2026 and its second blood-cancer deal in a week.
Scrip - April 27, 2026
Hard-Hit UK Biotech Lifted By M&A And Financing In Q1
Many UK biotechs were starved of new funds in 2025, but the first quarter of this year saw a rise in overall dealmaking, plus two company buyouts by big pharma.
Scrip - April 27, 2026
Many UK biotechs were starved of new funds in 2025, but the first quarter of this year saw a rise in overall dealmaking, plus two company buyouts by big pharma.
Scrip - April 27, 2026
QL Biopharm Unveils Oral Once-Weekly GLP-1 Peptide
Beijing-based QL Biopharm plans to progress the oral GLP-1 peptide ZT006 into a Phase II study to evaluate its once-weekly dosing potential in weight management in the fourth quarter.
Scrip - April 27, 2026
Beijing-based QL Biopharm plans to progress the oral GLP-1 peptide ZT006 into a Phase II study to evaluate its once-weekly dosing potential in weight management in the fourth quarter.
Scrip - April 27, 2026
Sun Makes Bold Bet With $11.75bn Organon Deal
Sun snaps up Organon in a deal that is set to transform India’s top-ranked drug maker’s standing globally, giving it global scale and a commanding position in areas like women’s health, established brands and biosimilars.
Scrip - April 27, 2026
Sun snaps up Organon in a deal that is set to transform India’s top-ranked drug maker’s standing globally, giving it global scale and a commanding position in areas like women’s health, established brands and biosimilars.
Scrip - April 27, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Iran blockade’s impact on global pharma; Bayer loyal to Europe but wants more; Kailera’s big IPO; 2025’s top drugs; Anthropic taps Novartis’s CEO.
Scrip - April 27, 2026
In this week's episode: Iran blockade’s impact on global pharma; Bayer loyal to Europe but wants more; Kailera’s big IPO; 2025’s top drugs; Anthropic taps Novartis’s CEO.
Scrip - April 27, 2026
Edwards Lifesciences Raises Guidance After TAVR Growth Leads Strong Q1
Edwards Lifesciences beat first-quarter expectations in every segment and raised its full-year outlook. The TAVR segment saw 11% growth as major competitors showed weakness – and with the possibility of new Medicare coverage on the horizon, the expansion may continue.
Medtech Insight - April 24, 2026
Edwards Lifesciences beat first-quarter expectations in every segment and raised its full-year outlook. The TAVR segment saw 11% growth as major competitors showed weakness – and with the possibility of new Medicare coverage on the horizon, the expansion may continue.
Medtech Insight - April 24, 2026
Nectero’s EAST System Slows AAA Growth In 90% Of Patients Over Two Years
Boston Scientific-backed company’s PGG therapy limited the growth of abdominal aortic aneurysms, with 90% of AAAs growing more slowly than expected; a Phase II/III trial is ongoing.
Medtech Insight - April 24, 2026
Boston Scientific-backed company’s PGG therapy limited the growth of abdominal aortic aneurysms, with 90% of AAAs growing more slowly than expected; a Phase II/III trial is ongoing.
Medtech Insight - April 24, 2026
MedCon Day 3: Tarver Continues To Hammer Home Use Of Medical Devices
CDRH director Michelle Tarver closed out MedCon 2026 by highlighting the center’s focus on patients and meeting the challenges presented by a rapidly evolving medtech landscape. She also discussed the center’s home health initiative and noted the importance of digital health.
Medtech Insight - April 24, 2026
CDRH director Michelle Tarver closed out MedCon 2026 by highlighting the center’s focus on patients and meeting the challenges presented by a rapidly evolving medtech landscape. She also discussed the center’s home health initiative and noted the importance of digital health.
Medtech Insight - April 24, 2026
FreeStyle Libre 3 Recall: 7 Deaths, 860 Injuries, and Now Complaints From India
Abbott's FreeStyle Libre 3 recall – linked with 860 serious injuries, seven deaths, Class I FDA classification – describes sensors reading lower than actual glucose levels. An Indian physician says three of his sensors showed the same issue, while Abbott says Indian sensors meet global standards.
Medtech Insight - April 24, 2026
Abbott's FreeStyle Libre 3 recall – linked with 860 serious injuries, seven deaths, Class I FDA classification – describes sensors reading lower than actual glucose levels. An Indian physician says three of his sensors showed the same issue, while Abbott says Indian sensors meet global standards.
Medtech Insight - April 24, 2026
FDA Issues Early Alert On Medline Syringes
The FDA flagged Medline's angiographic syringes as potentially posing a high risk to patients after a rotating adapter component was found to unwind during use, which could cause biohazard exposure or air embolism.
Medtech Insight - April 24, 2026
The FDA flagged Medline's angiographic syringes as potentially posing a high risk to patients after a rotating adapter component was found to unwind during use, which could cause biohazard exposure or air embolism.
Medtech Insight - April 24, 2026
EU Unlocks New Funding For Health AI Projects
Seven calls for proposals totaling €63.2m offer a glimpse into the EU’s priorities for AI and digital health.
Medtech Insight - April 24, 2026
Seven calls for proposals totaling €63.2m offer a glimpse into the EU’s priorities for AI and digital health.
Medtech Insight - April 24, 2026
Thermo Fisher Raises Guidance As Q1 Results Dodge Tariff Concerns
Company saw Q1 revenues grow by 6%, but shares slid as analysts questioned growth structure.
Medtech Insight - April 24, 2026
Company saw Q1 revenues grow by 6%, but shares slid as analysts questioned growth structure.
Medtech Insight - April 24, 2026
Premium Supplements Grow But Nutrition Sales Down For Nestlé
Infant formula recall hits sales at Nestlé's Nutrition business, which now houses the firm's dietary supplement lines following an organizational shake-up.
HBW Insight - April 27, 2026
Infant formula recall hits sales at Nestlé's Nutrition business, which now houses the firm's dietary supplement lines following an organizational shake-up.
HBW Insight - April 27, 2026
Hikma Abandons 503B Compounding And Strikes Fresh Inhalers Deal
Recently-reinstalled Hikma CEO Said Darwazah is wasting no time in taking action to turn the business around and restore focus, bringing to an end the company’s 503B compounding venture in the US at the same time as striking a fresh device technology to support its planned generic Ellipta inhalers.
Generics Bulletin - April 27, 2026
Recently-reinstalled Hikma CEO Said Darwazah is wasting no time in taking action to turn the business around and restore focus, bringing to an end the company’s 503B compounding venture in the US at the same time as striking a fresh device technology to support its planned generic Ellipta inhalers.
Generics Bulletin - April 27, 2026
Formycon Sets Out Growth Strategy After Missing FY2025 Financial Guidance
German biosimilars developer Formycon presented a four-pillar strategy to drive geographic expansion, portfolio growth, operational excellence, and cost efficiency, as it targets positive €60m-€70m in revenue for 2026.
Generics Bulletin - April 27, 2026
German biosimilars developer Formycon presented a four-pillar strategy to drive geographic expansion, portfolio growth, operational excellence, and cost efficiency, as it targets positive €60m-€70m in revenue for 2026.
Generics Bulletin - April 27, 2026
Sun Speeds Into Biosimilars With $11.75bn Organon Platform
Sun Pharma will acquire Organon in an $11.75bn deal, gaining an immediate global biosimilars platform, major China and Europe presence, while entering the world’s top 25 drugmakers after nearly doubling revenues.
Generics Bulletin - April 27, 2026
Sun Pharma will acquire Organon in an $11.75bn deal, gaining an immediate global biosimilars platform, major China and Europe presence, while entering the world’s top 25 drugmakers after nearly doubling revenues.
Generics Bulletin - April 27, 2026
Editing Heart Disease Out Of Our DNA
Gene editing medicines for cardiovascular risk are fast becoming a reality, with early data that dwarfs the impact of statins.
In Vivo - April 27, 2026
Gene editing medicines for cardiovascular risk are fast becoming a reality, with early data that dwarfs the impact of statins.
In Vivo - April 27, 2026
Leaders Are Paying For The Wrong Skills, Report Finds
A recent Wharton/Accenture report shows biopharma workers are overselling the wrong skills, employers are rewarding the wrong ones and AI is accelerating the gap.
In Vivo - April 27, 2026
A recent Wharton/Accenture report shows biopharma workers are overselling the wrong skills, employers are rewarding the wrong ones and AI is accelerating the gap.
In Vivo - April 27, 2026